# Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

> **NCT00080535** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Lymphoma
- T-Cell
- Cutaneous

## Interventions

- **BIOLOGICAL:** LMB-2

## Key facts

- **NCT ID:** NCT00080535
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-30
- **Primary completion:** 2011-12-31
- **Final completion:** 2011-12-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080535, "Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00080535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*